Publications
Source: National Center for Biotechnology Information
- Effectiveness of percutaneous intervention for patients with obstructive hypertrophic cardiomyopathy and coronary artery disease.
- Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
- A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy—the Baylor experience (1996-2002).
- Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy.
- Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy.
- Images in cardiovascular medicine. Avoiding papillary muscle infarction with myocardial contrast echocardiographic guidance of nonsurgical septal reduction therapy for hypertrophic obstructive cardiomypathy.
- Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy.
- Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy.
- Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.
- Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.
- Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy.
- Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy.
- Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients.
- Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.
- Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy.
- Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
- Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy.
- Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy.
- Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up.
- Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
- Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy.
- Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy.
- Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
- Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
- Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
- Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
